Clinical trial
A Randomized, Placebo-controlled, Double-blind, Phase 2a Study to Evaluate the Clinical Efficacy, Safety, Tolerability, and Biomarker Effects of 2 Dose Levels of GT-02287 in Participants With Early Parkinson's Disease
NCT07280299 is registered in ClinicalTrials.gov with Gain Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-controlled, Double-blind, Phase 2a Study to Evaluate the Clinical Efficacy, Safety, Tolerability, and Biomarker Effects of 2 Dose Levels of GT-02287 in Participants With Early Parkinson's Disease
- Lead sponsor
- Gain Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- May 30, 2026
- Completion date
- June 30, 2028
- Enrollment
- 111 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.